entertainment -WSS

entertainment

author：hotspot 2025-09-30 18:54:23 - browse：42

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Why you shouldn’t ask, “What country has the best health care?”

leisure time

WSS

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Tesla recalling nearly 16,000 of its 2021

Merck, Johnson & Johnson CEOs will testify on high drug prices

Venture capital firm's plans to take over Akron hospital face hurdles

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Study identifies new proteins linked to dementia risk 25 years later

Wikipedia

entertainment

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

Humana’s losses in Medicare Advantage tank its stock

Activists slam private health insurers over coverage restrictions

Affordable Connectivity Program vital to health care, experts say

BioMarin wins approval for gene therapy to treat hemophilia A

Wegovy leads to weight loss. Can it treat depression, too?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Virginia high school admissions case could be legal follow

Medicare Advantage insurers face 0.2% cut to 2025 payments

entertainment

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Why you shouldn’t ask, “What country has the best health care?”

Venture capital firm's plans to take over Akron hospital face hurdles

Merck CEO won’t testify in Senate, citing no expertise in drug prices

New clues to why women have higher risk of autoimmune disorders

Biogen walks away from Aduhelm, years after polarizing approval

leisure time

leisure time

leisure time

leisure time